TW200801200A - Methods for determining probability of an adverse or favorable reaction to a niacin receptor agonist - Google Patents
Methods for determining probability of an adverse or favorable reaction to a niacin receptor agonistInfo
- Publication number
- TW200801200A TW200801200A TW095129405A TW95129405A TW200801200A TW 200801200 A TW200801200 A TW 200801200A TW 095129405 A TW095129405 A TW 095129405A TW 95129405 A TW95129405 A TW 95129405A TW 200801200 A TW200801200 A TW 200801200A
- Authority
- TW
- Taiwan
- Prior art keywords
- gpr109a
- individual
- probability
- receptor
- amino acid
- Prior art date
Links
- 108700010041 Nicotinic acid receptor Proteins 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 239000000018 receptor agonist Substances 0.000 title abstract 2
- 229940044601 receptor agonist Drugs 0.000 title abstract 2
- 230000002411 adverse Effects 0.000 title 1
- 230000002349 favourable effect Effects 0.000 title 1
- 101000843809 Homo sapiens Hydroxycarboxylic acid receptor 2 Proteins 0.000 abstract 6
- 102100030643 Hydroxycarboxylic acid receptor 2 Human genes 0.000 abstract 6
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 150000007523 nucleic acids Chemical group 0.000 abstract 2
- 239000002773 nucleotide Substances 0.000 abstract 2
- 125000003729 nucleotide group Chemical group 0.000 abstract 2
- 206010067484 Adverse reaction Diseases 0.000 abstract 1
- 230000006838 adverse reaction Effects 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 238000011010 flushing procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70737205P | 2005-08-10 | 2005-08-10 | |
| PCT/US2006/031032 WO2007021744A1 (en) | 2005-08-10 | 2006-08-09 | Methods for determining probability of an adverse or favorable reaction to a niacin receptor agonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200801200A true TW200801200A (en) | 2008-01-01 |
Family
ID=37496834
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW095129405A TW200801200A (en) | 2005-08-10 | 2006-08-10 | Methods for determining probability of an adverse or favorable reaction to a niacin receptor agonist |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20090117559A1 (zh) |
| EP (1) | EP1924709A1 (zh) |
| TW (1) | TW200801200A (zh) |
| WO (1) | WO2007021744A1 (zh) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005051937A2 (en) * | 2003-11-21 | 2005-06-09 | Arena Pharmaceuticals, Inc. | 4-oxo-4,5-dihydro-furan-2-carboxylic and acid derivatives and methods of treatment of metabolic-related disorders thereof |
| US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
| US7750015B2 (en) | 2005-05-17 | 2010-07-06 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
| JP4975739B2 (ja) | 2005-05-17 | 2012-07-11 | シェーリング コーポレイション | 脂質異常症の処置のための、ニコチン酸受容体アゴニストとしての複素環 |
| KR20080091814A (ko) | 2006-01-20 | 2008-10-14 | 쉐링 코포레이션 | 지질혈증장애의 치료를 위한 니코틴산 수용체 효능제로서의헤테로사이클 |
| US20170042821A1 (en) * | 2007-07-01 | 2017-02-16 | Vitalis Llc | Combination tablet with chewable outer layer |
| WO2011057110A1 (en) * | 2009-11-06 | 2011-05-12 | Ruprecht-Karls-Universitat-Heidelberg | Gpr109a agonists for the treatment of cerebral ischemia |
| WO2014011926A1 (en) | 2012-07-11 | 2014-01-16 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| EP2732431B1 (en) * | 2011-07-15 | 2019-03-13 | Koninklijke Philips N.V. | Image processing for spectral ct |
| GB2497766A (en) * | 2011-12-20 | 2013-06-26 | Gene Onyx Ltd | Snp analysis to determine efficacy of skin care product |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5143854A (en) * | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5631734A (en) * | 1994-02-10 | 1997-05-20 | Affymetrix, Inc. | Method and apparatus for detection of fluorescently labeled materials |
| US6902902B2 (en) * | 2001-11-27 | 2005-06-07 | Arena Pharmaceuticals, Inc. | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders |
| GB0319126D0 (en) * | 2003-08-14 | 2003-09-17 | Smithkline Beecham Corp | Chemical compounds |
-
2006
- 2006-08-09 WO PCT/US2006/031032 patent/WO2007021744A1/en not_active Ceased
- 2006-08-09 EP EP06789628A patent/EP1924709A1/en not_active Withdrawn
- 2006-08-09 US US11/990,240 patent/US20090117559A1/en not_active Abandoned
- 2006-08-10 TW TW095129405A patent/TW200801200A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1924709A1 (en) | 2008-05-28 |
| WO2007021744A1 (en) | 2007-02-22 |
| US20090117559A1 (en) | 2009-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2735578C (en) | Method of identifying risk factors for alzheimer's disease comprising tomm40 gene variants | |
| WO2008013910A3 (en) | Methods for identifying, diagnosing, and predicting survival of lymphomas | |
| WO2008029130A3 (en) | Method of detecting and predicting ovulation and the period of fertility | |
| WO2005082110A3 (en) | Haplotype markers for diagnosing susceptibility to immunological conditions | |
| GB2477868A (en) | Methods and systems for incorporating multiple environmental and genetic risk factors | |
| TW200801200A (en) | Methods for determining probability of an adverse or favorable reaction to a niacin receptor agonist | |
| MX343863B (es) | Conjunto de sondas de oligonucleotido y metodos para perfilado de microbiotica. | |
| WO2003047420A3 (en) | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors | |
| HU0400904D0 (en) | Use of genes as molecular markers in diagnosis of schizophrenia and diagnostic kit for the same | |
| NZ598009A (en) | Genetic markers associated with risk of diabetes mellitus | |
| NZ591711A (en) | A method for predicting athletic performance potential | |
| WO2010103292A3 (en) | A genotyping tool for improving the prognostic and clinical management of ms patients | |
| WO2003072828A3 (en) | Fcgammariib polymorphisms detection in system lupus erythematosus | |
| MXPA05008793A (es) | Metodos para la prediccion de posibilidad de suicidio durante el tratamiento. | |
| IL174195A0 (en) | Compositions, reagents and kits for and methods of diagnosing, monitoring and treating obesity and/or diabetes | |
| WO2009011297A1 (ja) | Ｊａｋ２遺伝子の変異検出用プローブおよびその用途 | |
| NZ593392A (en) | Biomarker for detecting bladder cancer | |
| WO2007025989A3 (en) | Nucleic acid variants in the toll like receptor genes associated with altered innate immunity | |
| GB0713364D0 (en) | Abnormal blood conditions | |
| DE602004021366D1 (zh) | ||
| WO2008018789A3 (en) | Methods and means for diagnosing and treatment of osteoarthritis | |
| IL182383A0 (en) | Double hybrid system based on gene silencing by transcriptional interference | |
| ATE515576T1 (de) | Protein c polymorphismen | |
| WO2012024189A3 (en) | Compositions and methods for determining predisposition to developing metabolic syndrome | |
| WO2004002295A3 (en) | Diagnosing predisposition to fat deposition and associated condition |